Table 7.
L5 Trabecular Parameters: Anticatabolic Therapies
| Group | L5 Tb.N | L5 Tb.Th | L5 Tb.Sp | |||
|---|---|---|---|---|---|---|
| VEH: WT/Nmp4−/− | 3.71 ± 0.21/3.79 ± 0.15 | 0.051 ± 0.003/0.054 ± 0.003 | 0.250 ± 0.013/0.239 ± 0.017 | |||
| ALN: WT/Nmp4−/− | 3.81 ± 0.29/3.66 ± 0.27 | 0.051 ± 0.003/0.055 ± 0.003 | 0.247 ± 0.008/0.241 ± 0.018 | |||
| ZOL: WT/Nmp4−/− | 5.08 ± 0.89/4.42 ± 0.54 | 0.049 ± 0.004/0.053 ± 0.001 | 0.232 ± 0.028/0.233 ± 0.021 | |||
| RAL: WT/Nmp4−/− | 4.01 ± 0.40/4.44 ± 0.34 | 0.049 ± 0.003/0.054 ± 0.002 | 0.245 ± 0.026/0.230 ± 0.019 | |||
| Anticatabolic therapy | G: | P = 0.4554 | G: | P < 0.0001 | G: | P = 0.12 |
| T: | P < 0.0001 | T: | P = 0.31 | T: | P = 0.23 | |
| ZOL | A | GxT: | P = 0.87 | GxT: | P = 0.64 | |
| RAL | B | |||||
| VEH | C | |||||
| ALN | C | |||||
| GxT: | P = 0.0067 | |||||
The micro-CT analyses of the L5 trabecular architecture in mice treated with the anticatabolic therapies. The data were analyzed using two-way analyses of variance to compare the anabolic therapies and the anticatabolic monotherapies. Statistical significance was set at P ≤ 0.05, and levels not connected by the same letter are significantly different. The data represent mean ± standard deviation, n = 7 to 12 mice per group.
Abbreviations: G, genotype; T, treatment.